For primary hyperlipidemia. ANDA 206015, held by Aurobindo Pharma. Pitavastatin Calcium.
As of Nov 21, 2026, ANDA 206015 (Pitavastatin Calcium), held by Aurobindo Pharma, was first approved by FDA on Dec 20, 2016, with 5 approved supplements and 0 published complete response letters.
Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 20, 2016 | Original application | Approved |
| Pitavastatin CalciumEQ 1MG BASE ยท tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 2MG BASE ยท tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 4MG BASE ยท tablet;oral | Pitavastatin Calcium | Rx |
| Jun 11, 2024 | Supplement 8Labeling ยท Standard review | Approved | None posted |
| Jun 2, 2023 | Supplement 6Labeling ยท Standard review | Approved | None posted |
| Jun 2, 2023 | Supplement 7Labeling ยท Standard review | Approved | None posted |
| Jun 24, 2020 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Jun 24, 2020 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Dec 20, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters